Objective: To report two new cases of HIV-related pulmonary hypertension and to review and analyze the existing reports on the subject. Method: Two new cases of HIV-related pulmonary hypertension are described, and the cases, case series, and related articles on the subject in all languages were identified through a comprehensive MEDLINE search. Results: Among the 131 reviewed cases, 54% were male, and the age range was 2 to 56 years (mean, 33 years). The interval between the diagnosis of HIV disease and the diagnosis of pulmonary hypertension was 33 months. In 82% of cases, pulmonary hypertension was related solely to HIV infection. Presenting symptoms were progressive shortness of breath (85%), pedal edema (30%), nonproductive cough (19%), fatigue (13%), syncope or near-syncope (12%), and chest pain (7%). The mean (؎ SD) pulmonary arterial systolic BP was 67 ؎ 18 mm Hg (n ‫؍‬ 116), and diastolic BP was 40 ؎ 11 mm Hg (n ‫؍‬ 39). Pulmonary vascular resistance was 983 ؎ 420 dyne ⅐ s ⅐ cm ؊5 (n ‫؍‬ 29). Chest radiographs demonstrated cardiomegaly (72%) and pulmonary artery prominence (71%). Right ventricular hypertrophy was the most common electrocardiographic finding (67%). Dilatation of the right heart chambers was the most common echocardiographic finding (98%). Plexogenic pulmonary arteriopathy was the most common histopathology (78%). Pulmonary function tests demonstrated mild restrictive patterns with variably reduced diffusing capacities. The responses to vasodilator agents and antiretroviral therapy was variable. Sixty-six patients died during a median follow-up period of 8 months. The median length of time from diagnosis to death was 6 months. Conclusion: HIV infection is an independent risk factor for the development of pulmonary hypertension. The appearance of unexplained cardiopulmonary symptoms in HIV-infected individuals should suggest pulmonary hypertension.
acquired through heterosexual contact, had been diagnosed 12 years before. The CD4 cell count was zero. A chest radiograph demonstrated cardiomegaly with hilar prominence. ECG findings demonstrated sinus rhythm with right ventricular hypertrophy. A transthoracic echocardiogram revealed dilatation of the right heart chambers, paradoxical motion of the ventricular septum, moderate tricuspid regurgitation with an estimated systolic pulmonary artery pressure of 75 mm Hg, normal left ventricular systolic function, and no evidence of intracardiac shunting. A transthoracic echocardiogram that had been performed 3 months previously had demonstrated similar findings with estimated systolic pulmonary artery pressure of 63 mm Hg. The pulmonary function tests demonstrated the following: FVC, 3.4 L (103% of predicted); FEV 1 , 2.76 L (110% of predicted); total lung capacity, 5.4 L (103% of predicted); and diffusion capacity, 17.3 mL/min/mm Hg (82% of predicted). Bronchoscopy was performed, which did not reveal any significant abnormality. The patient underwent an open lung biopsy, which demonstrated focal small artery endothelial hyperplasia, intraluminal thrombus, and muscular hyperplasia. Biopsy specimens were negative in direct immunofluorescence studies in which fluorescence-conjugated antisera to complement C3 and C4 as well as IgG, IgM, and IgA were tested. Right heart catheterization was performed to evaluate the response of the elevated pulmonary arterial pressure to calcium channel blocker therapy. Baseline parameters, including pulmonary artery pressures, pulmonary vascular resistance, BP, and cardiac output, were measured, and the patient was administered 30 mg diltiazem orally. Thereafter, diltiazem, 60 mg orally, was administered every hour for three doses, and the hemodynamic measurements were obtained before each dose and also 2 h after the last dose. The mean pulmonary artery pressure dropped by 42% (42 to 28 mm Hg), and pulmonary vascular resistance decreased by 58% (616 to 257 dyne ⅐ s ⅐ cm
Ϫ5
) at 2 h after the last dose compared with the baseline values, without any significant change in BP and cardiac output. Diltiazem was prescribed at a dose of 120 mg every 6 h orally. The patient's condition continued to decline with repeated hospitalizations for various conditions. She developed large-cell-type malignant B-cell lymphoma and died 9 months after the initial diagnosis of pulmonary hypertension.
Case Report 2
A 48-year-old man was evaluated for worsening shortness of breath on exertion. He had no history of orthopnea, cough, wheezing, fever, or chest pain. His medical history included HIV infection for the previous 10 years, which was contracted though IV drug abuse. He did not suffer from any opportunistic infection. His CD4 count was 370 cells/mm 3 . A chest radiograph demonstrated cardiomegaly and prominent pulmonary vessels. ECG demonstrated sinus rhythm with right axis deviation and right bundle branch block. The ventilation-perfusion scan ruled out thromboembolic disease of the pulmonary arteries. The pulmonary function tests revealed mild obstructive and restrictive patterns. A transthoracic echocardiogram demonstrated dilated right-sided heart chambers with a right ventricular pressure overload pattern, moderate to severe tricuspid regurgitation, and an estimated pulmonary artery pressure of 90 mm Hg with no evidence of intracardiac shunting. The patient was prescribed oral anticoagulation therapy in addition to antiretroviral therapy and has been followed-up in the clinic for Ͼ 3 years.
Data Collection and Analysis
The MEDLINE (National Library of Medicine; Bethesda, MD) search of the literature was performed using the following key words: human immunodeficiency virus, HIV, acquired immunodeficiency syndrome, and AIDS, which were cross-referenced with word pulmonary hypertension. The references of the articles were examined for additional cases. All foreign language articles were translated with the help of other physicians who were familiar with those languages. All articles were evaluated by one of the authors. All adult and pediatric cases were included. Data were manually extracted from all cases, case series, and studies, and emphasis was placed to arrange and formulate all information and observations reported so far into a format that provides a brief but comprehensive overview of the subject. One hundred twenty-nine cases of HIV-related pulmonary hypertension reported previously were identified. All 131 cases (including 2 presented in this article) were analyzed for clinical characteristics, ECG and echocardiographic findings, hemodynamics, pathology, management, and prognosis of HIV-related pulmonary hypertension. The analysis was performed using computer software (SPSS, version 7.0; SPSS Inc; Chicago, IL).
Results
All cases of HIV-related pulmonary hypertension are summarized in Tables 1 and 2 . Among the 131 cases of HIV-related pulmonary hypertension, 54% were male. Age at the time of diagnosis of pulmonary hypertension ranged from 2 to 56 years (mean, 33 years). IV drug abuse was the most common risk factor for HIV infection (58%); other risk factors included homosexual behavior (22%) and hemophilia (9%). The average time interval between the diagnosis of HIV infection and the diagnosis of pulmonary hypertension was 33 months, while in 6% of cases, the diagnosis of HIV infection was established after the diagnosis of pulmonary hypertension. No correlation existed between CD4 cell counts (range, 0 to 937 cells/mm 3 ; mean, 269 cells/mm 3 ) or the presence of opportunistic infection and the development and progression of pulmonary hypertension. In 23 cases (18%), confounding factors for secondary pulmonary hypertension were present, while in the other 82% of cases, the development of pulmonary hypertension was not related to any other condition but the HIV infection.
Progressive shortness of breath was the most common presenting symptom (85%). Other presenting symptoms included pedal edema (30%), nonproductive cough (19%), fatigue (13%), syncope or near-syncope (12%), and chest pain (7%). The time interval between the onset of symptoms and the establishment of the diagnosis of pulmonary hypertension was about 6 months. The findings on physical examination were the following: loud P 2 ; right-sided S 3 gallop; murmurs of tricuspid and pulmonic regurgitation; increased jugular venous pressure; and peripheral edema. The chest radiographs demonstrated cardiomegaly (72%) and pulmonary artery prominence (71%). The ECG findings included right ventricular hypertrophy (67%), right-axis deviation (21%), right atrial abnormality (17%), and sinus tachycardia (16%). The echocardiographic findings reported were right heart chamber enlargement (98%), tricuspid regurgitation (64%), and paradoxical septal motion (40%).
A diagnosis of pulmonary hypertension was confirmed in most cases by cardiac catheterization after the initial diagnosis by echocardiography. The mean (Ϯ SD) systolic pulmonary arterial pressure was 67 Ϯ 18 mm Hg (range, 33 to 120 mm Hg; median, 61 mm Hg) (n ϭ 116). The diastolic pulmonary arterial pressure was 40 Ϯ 11 mm Hg (range, 21 to 70 mm Hg; median, 40 mm Hg) (n ϭ 39). The pulmonary vascular resistance was 983 Ϯ 420 dyne ⅐ s ⅐ cm Ϫ5 (range, 490 to 1,943 dyne ⅐ s ⅐ cm
Ϫ5
; median, 804 dyne ⅐ s ⅐ cm Ϫ5 ) (n ϭ 29). Ventilation-perfusion scans, if performed, were negative for pulmonary embolism. A mildly restrictive pattern with variably reduced diffusing capacity was noted in cases where the pulmonary function tests were performed. Histopathologic findings were available in 46 patients. Of these, 36 patients (78%) demonstrated plexogenic pulmonary arteriopathy, 5 (11%) demonstrated medial hypertrophy and intimal fibrosis without plexiform lesions, 3 (7%) demonstrated pulmonary veno-occlusive disease, and 2 (4%) demonstrated thrombotic pulmonary arteriopathy ( Table 1) .
The drugs used in the treatment of HIV-related pulmonary hypertension included pulmonary vasodilator agents (calcium channel blockers and epoprostenol), antiretroviral agents, diuretics, warfarin, nitrates, oxygen, and digoxin. The vasodilators were administered to 26 patients, antiretroviral agents in 26 patients, diuretics in 15 patients, and warfarin in 8 patients. The response to various treatments, including therapy with pulmonary vasodilators and antiretroviral agents, was variable and was impossible to measure from these case reports. Sixty-six cases were reported to be fatal during the median follow-up period of 8 months (range, 1 day to 40 months). The median time from the diagnosis of pulmonary hypertension to death was 6 months (range, 1 day to 40 months). Of the 66 cases reported to be fatal, 42 deaths (64%) were attributed to the consequences of pulmonary hypertension, including right heart failure, cardiogenic shock, and sudden death.
Discussion

Historical Background
In 1987, Kim and Factor 1 described for the first time pulmonary hypertension in an HIV-infected patient with hemophilia and membranoproliferative glomerulonephritis. Subsequently, in 1988, five cases of classic hemophilia with HIV infection and pulmonary hypertension were reported. 2 Initially, it was considered that pulmonary hypertension in these cases was secondary to hemophilia or to the use of the therapeutically lyophilized factor VII concentrate. Thereafter, many cases of HIV-related pulmonary hypertension have been described in patients for whom no factor other than the HIV infection could explain the presence of pulmonary hypertension. By the time of the writing of this article, about 131 cases demonstrating the coexistence of HIV infection with pulmonary hypertension had been reported (Tables 1, 2) . 
Pathology
The histopathology of HIV-associated pulmonary vasculopathy was similar to that of primary pulmonary vascular disease. The histopathology of primary pulmonary vascular disease is classified as primary pulmonary arteriopathy (plexiform arteriopathy, thrombotic arteriopathy, isolated medial hypertrophy, and medial hypertrophy with intimal fibrosis), pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis. 45 The plexogenic pulmonary arteriopathy was the most common histopathologic finding in patients with HIV-related pulmonary hypertension, followed by thrombotic pulmonary arteriopathy, pulmonary medial hypertrophy with intimal fibrosis, and pulmonary veno-occlusive disease. Plexogenic pulmonary arteriopathy also has been reported in cases of pulmonary hypertension related to other nonpulmonary conditions such as cirrhosis of the liver, portal hypertension, connective tissue disorders, and congenital cardiac disorders. 46 In the majority of the cases of HIV-related pulmonary hypertension, the development of pulmonary hypertension was solely related to HIV infection. This observation demonstrates that HIV infection itself plays a major role in the development of pulmonary hypertension, though not by a direct viral action because attempts to locate evidence of HIV in human lung tissue by either electron microscopy or by a variety of immunohistochemical techniques including in situ hybridization and polymerase chain reaction have been unsuccessful. 15 Similarly, in an animal study of monkeys infected with simian immunodeficiency virus, a retrovirus with homology to HIV, 19 of 85 monkeys developed an arteriopathy similar to that seen in HIV-related pulmonary hypertension, but the presence of the virus or viral DNA in pulmonary endothelial cells was not demonstrated. 47 There are no published data demonstrating that the cultured endothelial cells support the growth of HIV. 48 The exact mechanism of the development of pulmonary hypertension in HIV disease is not clear, though a number of postulated explanations exist. 15 The most dominant histopathologic finding in cases of HIV-related pulmonary hypertension is plexiform arteriopathy. Perivascular inflammation has been detected in cases of plexiform pulmonary hypertension, which suggests that different inflammatory mediators and growth factors derived from the inflammatory cells may play a role in the development of pulmonary hypertension. 49, 50 Increased expression of vascular endothelial growth factor-A in Tcells has been demonstrated in cases of HIV infection. 51 Vascular endothelial growth factor-A increases vascular permeability and is a potent inducer of endothelial cells. Increased expression of intrapulmonary platelet-derived growth factor also has been demonstrated in cases of HIV-associated pulmonary vasculopathy. 52 HIV proteins have been shown to activate endothelial cells and to release different cellular mediators. Glycoprotein-120, an HIV-1 envelope glycoprotein, has been found to stimulate the production of endothelin-1 and tissue necrosis factor-␣ in a concentration-dependent manner, and a chronically increased expression of endothelin-1 in HIV-infected patients has been demonstrated. 53 Exogenous tat protein, an HIV gene product that functions as a transcriptor for HIV replication, has been shown to have synergy with tumor necrosis factor and activate endothelial cells, a process that directly results in the release of epidermal growth factor, transforming growth factor-␤, platelet-derived growth factor, and interleukin-6. 49, 54 The alterations in the pulmonary endothelial cell homeostasis seem to be the most likely pathologic mechanism underlying the development of pulmonary hypertension in HIV-disease. 43 Genetic predisposition may have a role in the development of HIV-related pulmonary hypertension, since it is not related to the degree of immunosuppression and the CD4 cell count and since only a minority of HIV-infected individuals develop pulmonary hypertension. The human leukocyte antigen (HLA) system has been shown to play a role in the predisposition to pulmonary hypertension in HIV disease, and an increased prevalence of HLA-DR6 and HLA-DR52 has been demonstrated in patients with pulmonary hypertension and HIV disease. 34 An identical phenomenon has been observed with the development of a CD8 lymphocytic host response in patients with diffuse infiltrative lymphocytosis syndrome, the postulation being that a similar host mechanism in response to the HIV infection may be a function of HLA-DR alleles that are located within the major histocompatibility complex. 34 
Clinical Features
Progressive shortness of breath was the most common presenting symptom in cases of HIV-related pulmonary hypertension, followed by pedal edema, nonproductive cough, fatigue, syncope or near-syncope, and chest pain. The presenting symptoms and clinical features that were revealed on physical examination of patients with HIV-related pulmonary hypertension were not different from those reported for patients with primary pulmonary hypertension, but the time interval between the onset of symptoms and the establishment of diagnosis of pulmonary hypertension was shorter in patients with HIV-related pulmonary hypertension. 46, 55 The mean length of time from the onset of symptoms to the establishment of the diagnosis of pulmonary hypertension in HIV disease was about 6 months, which is in contrast with diagnoses of primary pulmonary hypertension in which that time has been 37 This difference might be due to the fact that patients with HIV disease are observed closely starting from the time of the initial diagnosis of HIV infection. The commonly reported chest radiograph findings of cardiomegaly and pulmonary artery prominence, the ECG findings of right ventricular hypertrophy, right atrial abnormality, and right axis deviation, and the echocardiographic findings of right heart chamber enlargement, tricuspid regurgitation, and paradoxical septal motion were also not different from other conditions where pulmonary hypertension is secondary to pulmonary vasculopathy. 46, 55 
Treatment
To date, no study determining the agent of choice for the treatment of HIV-related pulmonary hypertension exists. Pulmonary vasodilators and antiretroviral agents were used most commonly in the treatment of HIV-related pulmonary hypertension. A study comparing the effect of epoprostenol on patients with HIV-related pulmonary hypertension and those with primary pulmonary hypertension demonstrated similar vasodilatation in both groups. 26 Therapy with epoprostenol and calcium channel blockers have shown variable success rates in different case series. 14, 19, 26, 35 Oral anticoagulation therapy has been used in the treatment of the HIV-related pulmonary hypertension, though not enough supporting data exist regarding the effectiveness of the anticoagulation. 5, 13, 18, 30, 42 Many patients were treated for symptomatic improvement with diuretics, oxygen, and digoxin with variable results. 2, 4, 5, 14, 25, 41, 42 The role of antiretroviral agents in the treatment of HIV-related pulmonary hypertension is also not clear at this point. 35, 41 In a prospective study on the effect of antiretroviral treatment in patients with HIV-related pulmonary hypertension, the right ventricular systolic pressure/right atrial pressure gradient decreased by 3.2 mm Hg in six patients treated with antiretroviral agents and increased by 19 mm Hg in untreated patients. 35 On the basis of this observation, it was recommended that combination antiretroviral treatment be initiated in all patients with HIV-related pulmonary hypertension, irrespective of their CD4 counts or viral load. 35 On the other hand, another study using high-efficiency antiretroviral therapy, including protease inhibitors, failed to demonstrate any effect on the clinical course of pulmonary hypertension; in fact, two patients with a low viral load who were treated with high-efficiency antiretroviral agents demonstrated an accelerated course of pulmonary hypertension with worsening of pulmonary artery systolic pressures. 41 Prognosis HIV-related pulmonary hypertension is a grave disease. Half of the patients died during the median follow-up period of 8 months, with a median time interval from the diagnosis of pulmonary hypertension to death of 6 months. About two thirds of the deaths in patients with HIV-related pulmonary hypertension were due to the consequences of pulmonary hypertension, such as right-sided heart failure, cardiogenic shock, and sudden death. The development of pulmonary hypertension in HIV patients has been shown to reduce the probability of survival by half. 35 
Conclusion
This review reappraises the recognition of HIV virus as an independent risk factor for the development of pulmonary hypertension because the exclusiveness of HIV infection and the development of pulmonary hypertension was documented in most of the patients. The development and progression of pulmonary hypertension has no relationship with the stage of HIV disease. In some cases, the diagnosis of HIV disease was made after the diagnosis of pulmonary hypertension. Pulmonary arterial pressures were in the moderate-to-severe range. Plexogenic pulmonary arteriopathy was the most common histopathologic finding. Responses to pulmonary vasodilator agents, antiretroviral agents, and anticoagulation therapy were variable. Progressive shortness of breath and pedal edema were the two most common presenting features. The appearance of unexplained cardiopulmonary symptoms in HIV-infected individuals should suggest pulmonary hypertension.
